Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...